✦ LIBER ✦

Acneiform eruptions caused by an epidermal growth factor receptor-tyrosine kinase inhibitor ZD 1839

✍ Scribed by Gavin A Wong; Simon Nigen; Scott Walsh; Neil Shear

Book ID: 116578618
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 53 KB
Volume: 50
Category: Article
ISSN: 1097-6787
DOI: 10.1016/j.jaad.2003.10.159

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Acneiform lesions secondary to ZD1839, a

Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor

✍ M. Fernandez-Galar; A. España; J. M. López-Picazo 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 155 KB

Pharmacokinetics and Tolerability of the

Pharmacokinetics and Tolerability of the Orally Active Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Healthy Volunteers

✍ Ms Helen Swaisland, Alison Laight, Lesley Stafford, Helen Jones, Charles Morris, 📂 Article 📅 2001 🏛 Springer International Publishing AG 🌐 English ⚖ 202 KB

Acneiform eruption induced by epidermal

Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours

✍ W. Jacot; D. Bessis; E. Jorda; M. Ychou; M. Fabbro; J-L. Pujol; B. Guillot 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 140 KB

Differential radiosensitisation by ZD183

Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines

✍ Maddineni, S B; Sangar, V K; Hendry, J H; Margison, G P; Clarke, N W 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 141 KB

The effect of ZD1839 (IressaTM), an epid

The effect of ZD1839 (IressaTM), an epidermal growth factor receptor tyrosine kinase inhibitor, in combination with cisplatin, on apoptosis in SCC-15 cells

✍ A. Al-Hazzaa; I. D. Bowen; P. Randerson; M. A. Birchall 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 202 KB

829 The epidermal growth factor receptor

829 The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘iressa’, ZD-1839) and the protein prenyltransferase inhibitor M365408 as potential therapeutics in bladder cancer

✍ J.L. Dominguez-Escrig; J. Kelly; B.R. Davies 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 192 KB